intra-striatal rAAV5-miHTT

GENETIC2 trials

Sponsors

UniQure Biopharma B.V.

Conditions

Huntington DiseaseHuntington's Disease

Phase 1

Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease

Active, not recruitingNCT04120493

UniQure Biopharma B.V.Huntington's Disease

Start: 2019-09-06End: 2029-12-31Target: 43Updated: 2025-10-21

Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease

Active, not recruitingNCT05243017

UniQure Biopharma B.V.Huntington Disease

Start: 2021-10-07End: 2029-10-07Updated: 2025-03-10

Related Papers

MicroRNAs in polyglutamine diseases: Mechanistic insights, circulating biomarkers, and emerging microRNA-based therapeutic strategies.

2026-09-09

Circular RNAs, miRNAs, and Exosomes: Their Roles and Importance in Amyloid-Beta and Tau Pathologies in Alzheimer's Disease.

2025-04-081 citations

Mechanism and Therapeutic Prospect of miRNAs in Neurodegenerative Diseases.

2023-11-2312 citations

Recent advances in RNA-targeting therapy for neurological diseases

Neural Regeneration Research2023-04-103 citations

An alternative splicing modulator decreases mutant HTT and improves the molecular fingerprint in Huntington's disease patient neurons.

2022-11-1050 citations

J05 Interim results from cohort 1 of the double-blind, dose-escalation phase I/II clinical trial of amt-130 (HD-genetrx-1) for early-stage huntington’s disease (HD)

2022-09-015 citations

Evolving inclusion criteria in early manifest Huntington’s disease (HD) to address striatal atrophy: Lessons from HD-GeneTRX-1, the first gene therapy trial (1809)

Neurology2021-04-131 citations